A more profound decrease of on-treatment NKG2D correlated to past history of HCC, EVR, and platelet count before treatment and at EOT, but didn’t correlate to AFP levels before treatment or at EOT (Fig 6B). This evidence concerns the gene AFP and hepatocellular carcinoma.